<i>ARID1A</i> alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy.

Also, multivariate analysis showed that ARID1A alterations predicted longer PFS after checkpoint blockade (HR (95% CI), 0.61 (0.39 to 0.94), p=0.02) and this result was independent of microsatellite instability or mutational burden; median overall survival time was also longer in ARID1A- altered versus wild-type tumors (31 months vs 20 months), but did not reach statistical significance (p=0.13).

also in 111,027 other papers

In the same way, when only patients without TMB-high were included to the analysis, patients with ARID1A -altered tumors (vs ARID1A wild-type) showed a trend towards longer PFS: HR (95% CI), 0.69 (0.43 to 1.08) although not statistically significant (p=0.10) (see online supplementary figure 3 ) (small numbers of patients precluded analysis of patients with MSI-high or TMB-high who had ARID1A alterations vs not).

also in 53,322 other papers